What is the clinical evidence from this study?

Study design: Other. Population: Doxorubicin-induced acute cardiotoxicity (n=50). Intervention: Berberine vs. Doxorubicin alone. Primary outcome: Serum creatine kinase isoenzyme (CK-MB) levels (p=<0.05).

February 9, 2018Oncology LettersOpen Access

Protective effect of berberine on acute cardiomyopathy associated with doxorubicin treatment

Q: What are the key findings of this study?

Berberine significantly attenuated doxorubicin-induced acute cardiotoxicity in rats, reducing serum CK-MB levels from 3404 U/l to 2123 U/l at the 20 mg/kg dose and preventing mitochondrial calcium overload.

View Full Paper

Ask AI

Bookmark

Key result

Berberine significantly attenuated doxorubicin-induced acute cardiotoxicity in rats, reducing serum CK-MB levels from 3404 U/l to 2123 U/l at the 20 mg/kg dose and preventing mitochondrial calcium overload.

Authors

XCXiong ChenUniversity of Science and Technology Beijing YWYanzhao WuHebei Medical University YZYu ZhangMemorial University of Newfoundland

Discussion

Member takes

Overview

Berberine may mitigate doxorubicin cardiotoxicity in rats; animal data leave open clinical translation.

PICO

Population

50 Sprague-Dawley rats weighing 200-250 g were used to evaluate the protective effects of berberine against doxorubicin-induced acute cardiotoxicity over a 10-day period.

Intervention / Comparator

Berberine vs Doxorubicin alone (5, 10, and 20 mg/kg orally once daily)

Primary Outcome

Serum creatine kinase isoenzyme (CK-MB) levels, p=<0.05

Main Result

Absolute Event Rate: 2123% vs 3404%

p-value: p=<0.05

Limitations

Animal model study, requiring further investigation for clinical translation
Specific and sensitive indicators for cardiac damage such as B-type natriuretic peptide (BNP) and troponins were not measured

Cite This Study

Chen et al. (2018) studied Doxorubicin-induced acute cardiotoxicity (n=50). Berberine vs. Doxorubicin alone was evaluated on Serum creatine kinase isoenzyme (CK-MB) levels (p=<0.05). Berberine significantly attenuated doxorubicin-induced acute cardiotoxicity in rats, reducing serum CK-MB levels from 3404 U/l to 2123 U/l at the 20 mg/kg dose and preventing mitochondrial calcium overload.

synapsesocial.com/papers/6a63d5cbb5b214049b7a712d https://doi.org/10.3892/ol.2018.8020

View Full Paper

Ask AI

Bookmark

February 9, 2018Oncology LettersOpen Access

Protective effect of berberine on acute cardiomyopathy associated with doxorubicin treatment

View Full Paper

Ask AI

Bookmark

Key result

Authors

XCXiong ChenUniversity of Science and Technology Beijing YWYanzhao WuHebei Medical University YZYu ZhangMemorial University of Newfoundland

Discussion

Member takes

Overview

Berberine may mitigate doxorubicin cardiotoxicity in rats; animal data leave open clinical translation.

PICO

Population

50 Sprague-Dawley rats weighing 200-250 g were used to evaluate the protective effects of berberine against doxorubicin-induced acute cardiotoxicity over a 10-day period.

Intervention / Comparator

Berberine vs Doxorubicin alone (5, 10, and 20 mg/kg orally once daily)

Primary Outcome

Serum creatine kinase isoenzyme (CK-MB) levels, p=<0.05

Main Result

Absolute Event Rate: 2123% vs 3404%

p-value: p=<0.05

Limitations

Animal model study, requiring further investigation for clinical translation
Specific and sensitive indicators for cardiac damage such as B-type natriuretic peptide (BNP) and troponins were not measured

Cite This Study

synapsesocial.com/papers/6a63d5cbb5b214049b7a712d https://doi.org/10.3892/ol.2018.8020

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark